🟢 Pacific Biosciences is trading 13.17% up today after positive Phase 3 melanoma-vaccine results

Pacific Biosciences is trading 13.17% up now at $1.29 after positive Phase 3 melanoma cancer-vaccine results from Moderna and Merck lifted biotechnology-sector sentiment.

• The trial showed improved recurrence-free and distant metastasis-free survival, sending Moderna and Merck sharply higher.
• No fresh Pacific Biosciences-specific announcement was identified; the move appears sector-driven rather than company-specific.